Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Surgery for temporal glioblastoma: lobectomy outranks oncosurgical-based gross-total resection.

Schneider M, Potthoff AL, Keil VC, Güresir Á, Weller J, Borger V, Hamed M, Waha A, Vatter H, Güresir E, Herrlinger U, Schuss P.

J Neurooncol. 2019 Oct;145(1):143-150. doi: 10.1007/s11060-019-03281-1. Epub 2019 Sep 4.

PMID:
31485921
2.

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.

Rahman MA, Gras Navarro A, Brekke J, Engelsen A, Bindesbøll C, Sarowar S, Bahador M, Bifulco E, Goplen D, Waha A, Lie SA, Gjertsen BT, Selheim F, Enger PØ, Simonsen A, Chekenya M.

Br J Cancer. 2019 Oct;121(7):545-555. doi: 10.1038/s41416-019-0551-1. Epub 2019 Aug 15.

PMID:
31413318
3.

Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.

Keupp K, Hampp S, Hübbel A, Maringa M, Kostezka S, Rhiem K, Waha A, Wappenschmidt B, Pujol R, Surrallés J, Schmutzler RK, Wiesmüller L, Hahnen E.

Mol Genet Genomic Med. 2019 Sep;7(9):e863. doi: 10.1002/mgg3.863. Epub 2019 Jul 25.

4.

Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide.

Potthoff AL, Heiland DH, Evert BO, Almeida FR, Behringer SP, Dolf A, Güresir Á, Güresir E, Joseph K, Pietsch T, Schuss P, Herrlinger U, Westhoff MA, Vatter H, Waha A, Schneider M.

Cancers (Basel). 2019 Jun 20;11(6). pii: E858. doi: 10.3390/cancers11060858.

5.

Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial.

Schunkert H, Boening A, von Scheidt M, Lanig C, Gusmini F, de Waha A, Kuna C, Fach A, Grothusen C, Oberhoffer M, Knosalla C, Walther T, Danner BC, Misfeld M, Zeymer U, Wimmer-Greinecker G, Siepe M, Grubitzsch H, Joost A, Schaefer A, Conradi L, Cremer J, Hamm C, Lange R, Radke PW, Schulz R, Laufer G, Grieshaber P, Pader P, Attmann T, Schmoeckel M, Meyer A, Ziegelhöffer T, Hambrecht R, Kastrati A, Sandner SE.

Eur Heart J. 2019 Aug 1;40(29):2432-2440. doi: 10.1093/eurheartj/ehz185.

PMID:
31145798
6.

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.

Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadaló L, Aalfs CM, Agata S, Aittomäki K, Alducci E, Alonso-Cerezo MC, Arnold N, Auber B, Austin R, Azzollini J, Balmaña J, Barbieri E, Bartram CR, Blanco A, Blümcke B, Bonache S, Bonanni B, Borg Å, Bortesi B, Brunet J, Bruzzone C, Bucksch K, Cagnoli G, Caldés T, Caliebe A, Caligo MA, Calvello M, Capone GL, Caputo SM, Carnevali I, Carrasco E, Caux-Moncoutier V, Cavalli P, Cini G, Clarke EM, Concolino P, Cops EJ, Cortesi L, Couch FJ, Darder E, de la Hoya M, Dean M, Debatin I, Del Valle J, Delnatte C, Derive N, Diez O, Ditsch N, Domchek SM, Dutrannoy V, Eccles DM, Ehrencrona H, Enders U, Evans DG, Farra C, Faust U, Felbor U, Feroce I, Fine M, Foulkes WD, Galvao HCR, Gambino G, Gehrig A, Gensini F, Gerdes AM, Germani A, Giesecke J, Gismondi V, Gómez C, Gómez Garcia EB, González S, Grau E, Grill S, Gross E, Guerrieri-Gonzaga A, Guillaud-Bataille M, Gutiérrez-Enríquez S, Haaf T, Hackmann K, Hansen TVO, Harris M, Hauke J, Heinrich T, Hellebrand H, Herold KN, Honisch E, Horvath J, Houdayer C, Hübbel V, Iglesias S, Izquierdo A, James PA, Janssen LAM, Jeschke U, Kaulfuß S, Keupp K, Kiechle M, Kölbl A, Krieger S, Kruse TA, Kvist A, Lalloo F, Larsen M, Lattimore VL, Lautrup C, Ledig S, Leinert E, Lewis AL, Lim J, Loeffler M, López-Fernández A, Lucci-Cordisco E, Maass N, Manoukian S, Marabelli M, Matricardi L, Meindl A, Michelli RD, Moghadasi S, Moles-Fernández A, Montagna M, Montalban G, Monteiro AN, Montes E, Mori L, Moserle L, Müller CR, Mundhenke C, Naldi N, Nathanson KL, Navarro M, Nevanlinna H, Nichols CB, Niederacher D, Nielsen HR, Ong KR, Pachter N, Palmero EI, Papi L, Pedersen IS, Peissel B, Perez-Segura P, Pfeifer K, Pineda M, Pohl-Rescigno E, Poplawski NK, Porfirio B, Quante AS, Ramser J, Reis RM, Revillion F, Rhiem K, Riboli B, Ritter J, Rivera D, Rofes P, Rump A, Salinas M, Sánchez de Abajo AM, Schmidt G, Schoenwiese U, Seggewiß J, Solanes A, Steinemann D, Stiller M, Stoppa-Lyonnet D, Sullivan KJ, Susman R, Sutter C, Tavtigian SV, Teo SH, Teulé A, Thomassen M, Tibiletti MG, Tischkowitz M, Tognazzo S, Toland AE, Tornero E, Törngren T, Torres-Esquius S, Toss A, Trainer AH, Tucker KM, van Asperen CJ, van Mackelenbergh MT, Varesco L, Vargas-Parra G, Varon R, Vega A, Velasco Á, Vesper AS, Viel A, Vreeswijk MPG, Wagner SA, Waha A, Walker LC, Walters RJ, Wang-Gohrke S, Weber BHF, Weichert W, Wieland K, Wiesmüller L, Witzel I, Wöckel A, Woodward ER, Zachariae S, Zampiga V, Zeder-Göß C, Investigators K, Lázaro C, De Nicolo A, Radice P, Engel C, Schmutzler RK, Goldgar DE, Spurdle AB.

Hum Mutat. 2019 Sep;40(9):1557-1578. doi: 10.1002/humu.23818.

7.

H3F3A-G34R mutant high grade neuroepithelial neoplasms with glial and dysplastic ganglion cell components.

Andreiuolo F, Lisner T, Zlocha J, Kramm C, Koch A, Bison B, Gareton A, Zanello M, Waha A, Varlet P, Pietsch T.

Acta Neuropathol Commun. 2019 May 20;7(1):78. doi: 10.1186/s40478-019-0731-5.

8.

Enzymatic Activity of HPGD in Treg Cells Suppresses Tconv Cells to Maintain Adipose Tissue Homeostasis and Prevent Metabolic Dysfunction.

Schmidleithner L, Thabet Y, Schönfeld E, Köhne M, Sommer D, Abdullah Z, Sadlon T, Osei-Sarpong C, Subbaramaiah K, Copperi F, Haendler K, Varga T, Schanz O, Bourry S, Bassler K, Krebs W, Peters AE, Baumgart AK, Schneeweiss M, Klee K, Schmidt SV, Nüssing S, Sander J, Ohkura N, Waha A, Sparwasser T, Wunderlich FT, Förster I, Ulas T, Weighardt H, Sakaguchi S, Pfeifer A, Blüher M, Dannenberg AJ, Ferreirós N, Muglia LJ, Wickenhauser C, Barry SC, Schultze JL, Beyer M.

Immunity. 2019 May 21;50(5):1232-1248.e14. doi: 10.1016/j.immuni.2019.03.014. Epub 2019 Apr 23.

PMID:
31027998
9.

Epigenetics of the molecular clock and bacterial diversity in bipolar disorder.

Bengesser SA, Mörkl S, Painold A, Dalkner N, Birner A, Fellendorf FT, Platzer M, Queissner R, Hamm C, Maget A, Pilz R, Rieger A, Wagner-Skacel J, Reininghaus B, Kapfhammer HP, Petek E, Kashofer K, Halwachs B, Holzer P, Waha A, Reininghaus EZ.

Psychoneuroendocrinology. 2019 Mar;101:160-166. doi: 10.1016/j.psyneuen.2018.11.009. Epub 2018 Nov 10.

PMID:
30465968
10.

Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features.

Andreiuolo F, Varlet P, Tauziède-Espariat A, Jünger ST, Dörner E, Dreschmann V, Kuchelmeister K, Waha A, Haberler C, Slavc I, Corbacioglu S, Riemenschneider MJ, Leipold A, Rüdiger T, Körholz D, Acker T, Russo A, Faber J, Sommer C, Armbrust S, Rose M, Erdlenbruch B, Hans VH, Bernbeck B, Schneider D, Lorenzen J, Ebinger M, Handgretinger R, Neumann M, van Buiren M, Prinz M, Roganovic J, Jakovcevic A, Park SH, Grill J, Puget S, Messing-Jünger M, Reinhard H, Bergmann M, Hattingen E, Pietsch T.

Brain Pathol. 2019 Mar;29(2):205-216. doi: 10.1111/bpa.12659. Epub 2018 Nov 11.

PMID:
30246434
11.

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.

Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, Zachariae S, Hauke J, Wappenschmidt B, Waha A, Blümcke B, Kiechle M, Meindl A, Niederacher D, Bartram CR, Speiser D, Schlegelberger B, Arnold N, Wieacker P, Leinert E, Gehrig A, Briest S, Kast K, Riess O, Emons G, Weber BHF, Engel J, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).

BMC Cancer. 2018 Mar 7;18(1):265. doi: 10.1186/s12885-018-4029-y.

12.

Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.

Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, Bison B, Claviez A, van Vuurden DG, von Bueren AO, Gessi M, Kühnle I, Hans VH, Benesch M, Sturm D, Kortmann RD, Waha A, Pietsch T, Kramm CM.

Neuro Oncol. 2018 Jan 10;20(1):123-131. doi: 10.1093/neuonc/nox149.

13.

New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma.

Ersoy TF, Keil VC, Hadizadeh DR, Gielen GH, Fimmers R, Waha A, Heidenreich B, Kumar R, Schild HH, Simon M.

Neuroradiology. 2017 Dec;59(12):1223-1231. doi: 10.1007/s00234-017-1920-1. Epub 2017 Sep 11.

PMID:
28894890
14.

Outcomes of patients treated with durable polymer platinum-chromium everolimus-eluting stents: a meta-analysis of randomised trials.

Cassese S, Ndrepepa G, Byrne RA, Kufner S, Xhepa E, de Waha A, Rheude T, Colleran R, Giacoppo D, Harada Y, Laugwitz KL, Schunkert H, Fusaro M, Kastrati A.

EuroIntervention. 2017 Oct 20;13(8):986-993. doi: 10.4244/EIJ-D-16-00871.

15.

MTSS1 is epigenetically regulated in glioma cells and inhibits glioma cell motility.

Luxen D, Gielen GH, Waha A, Isselstein L, Müller T, Koch P, Hammes J, Becker A, Simon M, Wurst P, Endl E, Pietsch T, Gessi M, Waha A.

Transl Oncol. 2017 Feb;10(1):70-79. doi: 10.1016/j.tranon.2016.11.006. Epub 2016 Dec 15.

16.

Is the molecular clock ticking differently in bipolar disorder? Methylation analysis of the clock gene ARNTL.

Bengesser SA, Reininghaus EZ, Lackner N, Birner A, Fellendorf FT, Platzer M, Kainzbauer N, Tropper B, Hörmanseder C, Queissner R, Kapfhammer HP, Wallner-Liebmann SJ, Fuchs R, Petek E, Windpassinger C, Schnalzenberger M, Reininghaus B, Evert B, Waha A.

World J Biol Psychiatry. 2018;19(sup2):S21-S29. doi: 10.1080/15622975.2016.1231421. Epub 2016 Oct 14.

PMID:
27739341
17.

Assessment of Promoter Methylation Identifies PTCH as a Putative Tumor-suppressor Gene in Human CLL.

Schmidt-Wolf IG, Plass C, Byrd JC, Frevel K, Pietsch T, Waha A.

Anticancer Res. 2016 Sep;36(9):4515-9.

PMID:
27630290
18.

A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investigator-Initiated trial.

de Waha A, Sandner S, von Scheidt M, Boening A, Koch-Buettner K, Hammel D, Hambrecht R, Danner BC, Schöndube FA, Goerlach G, Fischlein T, Schmoeckel M, Oberhoffer M, Schulz R, Walther T, Ziegelhöffer T, Knosalla C, Schönrath F, Beyersdorf F, Siepe M, Attmann T, Misfeld M, Mohr FW, Sievers HH, Joost A, Putman LM, Laufer G, Hamm C, Zeymer U, Kastrati A, Radke PW, Lange R, Cremer J, Schunkert H.

Am Heart J. 2016 Sep;179:69-76. doi: 10.1016/j.ahj.2016.05.017. Epub 2016 Jun 18.

PMID:
27595681
19.

CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways.

Schulte SL, Waha A, Steiger B, Denkhaus D, Dörner E, Calaminus G, Leuschner I, Pietsch T.

Oncotarget. 2016 Aug 23;7(34):55026-55042. doi: 10.18632/oncotarget.10392.

20.

Culprit lesion location and outcome in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial.

Fuernau G, Fengler K, Desch S, Eitel I, Neumann FJ, Olbrich HG, de Waha A, de Waha S, Richardt G, Hennersdorf M, Empen K, Hambrecht R, Jung C, Böhm M, Pöss J, Strasser RH, Schneider S, Ouarrak T, Schuler G, Werdan K, Zeymer U, Thiele H.

Clin Res Cardiol. 2016 Dec;105(12):1030-1041. Epub 2016 Jul 4.

PMID:
27378612
21.

The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.

Schaub C, Schäfer N, Mack F, Stuplich M, Kebir S, Niessen M, Tzaridis T, Banat M, Vatter H, Waha A, Herrlinger U, Glas M.

J Cancer Res Clin Oncol. 2016 Aug;142(8):1825-9. doi: 10.1007/s00432-016-2187-3. Epub 2016 Jun 18.

PMID:
27318492
22.

Altered splicing leads to reduced activation of CPEB3 in high-grade gliomas.

Skubal M, Gielen GH, Waha A, Gessi M, Kaczmarczyk L, Seifert G, Freihoff D, Freihoff J, Pietsch T, Simon M, Theis M, Steinhäuser C, Waha A.

Oncotarget. 2016 Jul 5;7(27):41898-41912. doi: 10.18632/oncotarget.9735.

23.

Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.

Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O.

J Neurooncol. 2016 Aug;129(1):93-100. doi: 10.1007/s11060-016-2144-7. Epub 2016 May 18.

PMID:
27193554
24.

Intramedullary gangliogliomas: histopathologic and molecular features of 25 cases.

Gessi M, Dörner E, Dreschmann V, Antonelli M, Waha A, Giangaspero F, Gnekow A, Pietsch T.

Hum Pathol. 2016 Mar;49:107-13. doi: 10.1016/j.humpath.2015.09.041. Epub 2015 Oct 31.

PMID:
26826417
25.

Dysembryoplastic Neuroepithelial Tumor of the Septum Pellucidum and the Supratentorial Midline: Histopathologic, Neuroradiologic, and Molecular Features of 7 Cases.

Gessi M, Hattingen E, Dörner E, Goschzik T, Dreschmann V, Waha A, Pietsch T.

Am J Surg Pathol. 2016 Jun;40(6):806-11. doi: 10.1097/PAS.0000000000000600.

PMID:
26796505
26.

Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.

van de Nes J, Gessi M, Sucker A, Möller I, Stiller M, Horn S, Scholz SL, Pischler C, Stadtler N, Schilling B, Zimmer L, Hillen U, Scolyer RA, Buckland ME, Lauriola L, Pietsch T, Waha A, Schadendorf D, Murali R, Griewank KG.

J Neurooncol. 2016 May;127(3):435-44. doi: 10.1007/s11060-015-2052-2. Epub 2016 Jan 7.

27.

High frequency of H3F3A (K27M) mutations characterizes pediatric and adult high-grade gliomas of the spinal cord.

Gessi M, Gielen GH, Dreschmann V, Waha A, Pietsch T.

Acta Neuropathol. 2015 Sep;130(3):435-7. doi: 10.1007/s00401-015-1463-7. Epub 2015 Aug 1. No abstract available.

PMID:
26231952
28.

Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock.

Unverzagt S, Buerke M, de Waha A, Haerting J, Pietzner D, Seyfarth M, Thiele H, Werdan K, Zeymer U, Prondzinsky R.

Cochrane Database Syst Rev. 2015 Mar 27;(3):CD007398. doi: 10.1002/14651858.CD007398.pub3. Review.

PMID:
25812932
29.

Gender differences in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial.

Fengler K, Fuernau G, Desch S, Eitel I, Neumann FJ, Olbrich HG, de Waha A, de Waha S, Richardt G, Hennersdorf M, Empen K, Hambrecht R, Fuhrmann J, Böhm M, Poess J, Strasser R, Schneider S, Schuler G, Werdan K, Zeymer U, Thiele H.

Clin Res Cardiol. 2015 Jan;104(1):71-8. doi: 10.1007/s00392-014-0767-2. Epub 2014 Oct 7.

PMID:
25287767
30.

Genetic Analysis of Diffuse High-Grade Astrocytomas in Infancy Defines a Novel Molecular Entity.

Gielen GH, Gessi M, Buttarelli FR, Baldi C, Hammes J, zur Muehlen A, Doerner E, Denkhaus D, Warmuth-Metz M, Giangaspero F, Lauriola L, von Bueren AO, Kramm CM, Waha A, Pietsch T.

Brain Pathol. 2015 Jul;25(4):409-17. doi: 10.1111/bpa.12210. Epub 2014 Dec 19.

PMID:
25231549
31.

TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.

Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M, Schramm J, Hemminki K, Waha A, Kumar R.

Neuro Oncol. 2015 Jan;17(1):45-52. doi: 10.1093/neuonc/nou158. Epub 2014 Aug 18.

32.

FGFR1 mutations in Rosette-forming glioneuronal tumors of the fourth ventricle.

Gessi M, Moneim YA, Hammes J, Goschzik T, Scholz M, Denkhaus D, Waha A, Pietsch T.

J Neuropathol Exp Neurol. 2014 Jun;73(6):580-4. doi: 10.1097/NEN.0000000000000080.

PMID:
24806303
33.

FGFR1 N546K mutation in a case of papillary glioneuronal tumor (PGNT).

Gessi M, Abdel Moneim Y, Hammes J, Waha A, Pietsch T.

Acta Neuropathol. 2014;127(6):935-6. doi: 10.1007/s00401-014-1283-1. Epub 2014 Apr 29. No abstract available.

PMID:
24777483
34.

Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.

Kufner S, Byrne RA, de Waha A, Schulz S, Joner M, Laugwitz KL, Kastrati A; Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2, (ISAR-DESIRE 2) Investigators.

Cardiovasc Revasc Med. 2014 Mar;15(2):69-75. doi: 10.1016/j.carrev.2014.02.001. Epub 2014 Feb 15.

PMID:
24684757
35.

Absence of TERT promoter mutations in primary melanocytic tumours of the central nervous system.

Gessi M, van de Nes J, Griewank K, Barresi V, Buckland ME, Kirfel J, Caltabiano R, Hammes J, Lauriola L, Pietsch T, Waha A.

Neuropathol Appl Neurobiol. 2014 Oct;40(6):794-7. doi: 10.1111/nan.12138. No abstract available.

PMID:
24645797
36.

Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials.

de Waha A, King LA, Stefanini GG, Byrne RA, Serruys PW, Meier B, Jüni P, Kastrati A, Windecker S.

EuroIntervention. 2015 Apr;10(12):1425-31. doi: 10.4244/EIJV10I12A247.

37.

Analysis of TET expression/activity and 5mC oxidation during normal and malignant germ cell development.

Nettersheim D, Heukamp LC, Fronhoffs F, Grewe MJ, Haas N, Waha A, Honecker F, Waha A, Kristiansen G, Schorle H.

PLoS One. 2013 Dec 26;8(12):e82881. doi: 10.1371/journal.pone.0082881. eCollection 2013.

38.

SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.

Trautmann M, Sievers E, Aretz S, Kindler D, Michels S, Friedrichs N, Renner M, Kirfel J, Steiner S, Huss S, Koch A, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Waha A, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W.

Oncogene. 2014 Oct 16;33(42):5006-16. doi: 10.1038/onc.2013.443. Epub 2013 Oct 28.

PMID:
24166495
39.

Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level.

Kmiecik J, Poli A, Brons NH, Waha A, Eide GE, Enger PØ, Zimmer J, Chekenya M.

J Neuroimmunol. 2013 Nov 15;264(1-2):71-83. doi: 10.1016/j.jneuroim.2013.08.013. Epub 2013 Aug 31.

40.

Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial.

Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, de Waha A, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Lauer B, Böhm M, Ebelt H, Schneider S, Werdan K, Schuler G; Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II) trial investigators.

Lancet. 2013 Nov 16;382(9905):1638-45. doi: 10.1016/S0140-6736(13)61783-3. Epub 2013 Sep 3.

PMID:
24011548
41.

FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.

Schaub C, Greschus S, Seifert M, Waha A, Blasius E, Rasch K, Landwehr C, Mack F, Schäfer N, Stuplich M, Kebir S, Vilz B, Scheffler B, Boström J, Simon M, Urbach H, Glas M, Herrlinger U.

Oncology. 2013;85(3):191-5. doi: 10.1159/000354692. Epub 2013 Sep 5.

PMID:
24008924
42.

Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials.

de Waha A, Stefanini GG, King LA, Byrne RA, Serruys PW, Kufner S, Meier B, Jüni P, Kastrati A, Windecker S.

Int J Cardiol. 2013 Oct 15;168(6):5162-6. doi: 10.1016/j.ijcard.2013.07.263. Epub 2013 Aug 13.

PMID:
23993323
43.

Genome-wide DNA copy number analysis of desmoplastic infantile astrocytomas and desmoplastic infantile gangliogliomas.

Gessi M, Zur Mühlen A, Hammes J, Waha A, Denkhaus D, Pietsch T.

J Neuropathol Exp Neurol. 2013 Sep;72(9):807-15. doi: 10.1097/NEN.0b013e3182a033a0.

PMID:
23965740
44.

Anticancer effects of niclosamide in human glioblastoma.

Wieland A, Trageser D, Gogolok S, Reinartz R, Höfer H, Keller M, Leinhaas A, Schelle R, Normann S, Klaas L, Waha A, Koch P, Fimmers R, Pietsch T, Yachnis AT, Pincus DW, Steindler DA, Brüstle O, Simon M, Glas M, Scheffler B.

Clin Cancer Res. 2013 Aug 1;19(15):4124-36. doi: 10.1158/1078-0432.CCR-12-2895.

45.

H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas.

Gielen GH, Gessi M, Hammes J, Kramm CM, Waha A, Pietsch T.

Am J Clin Pathol. 2013 Mar;139(3):345-9. doi: 10.1309/AJCPABOHBC33FVMO.

PMID:
23429371
46.

H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?

Gessi M, Gielen GH, Hammes J, Dörner E, Mühlen AZ, Waha A, Pietsch T.

J Neurooncol. 2013 Mar;112(1):67-72. doi: 10.1007/s11060-012-1040-z. Epub 2013 Jan 26.

PMID:
23354654
47.

Absence of KIAA1549-BRAF fusion in rosette-forming glioneuronal tumors of the fourth ventricle (RGNT).

Gessi M, Lambert SR, Lauriola L, Waha A, Collins VP, Pietsch T.

J Neurooncol. 2012 Oct;110(1):21-5. doi: 10.1007/s11060-012-0940-2. Epub 2012 Jul 20.

PMID:
22814862
48.

Intra-aortic balloon counterpulsation in patients with acute myocardial infarction without cardiogenic shock. A meta-analysis of randomized trials.

Cassese S, de Waha A, Ndrepepa G, Ranftl S, King L, Schömig A, Kastrati A.

Am Heart J. 2012 Jul;164(1):58-65.e1. doi: 10.1016/j.ahj.2012.05.001.

PMID:
22795283
49.

RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas.

von dem Knesebeck A, Felsberg J, Waha A, Hartmann W, Scheffler B, Glas M, Hammes J, Mikeska T, Yan PS, Endl E, Simon M, Reifenberger G, Pietsch T, Waha A.

Neoplasia. 2012 Jun;14(6):526-34.

50.

GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system.

Gessi M, Hammes J, Lauriola L, Dörner E, Kirfel J, Kristiansen G, zur Muehlen A, Denkhaus D, Waha A, Pietsch T.

Neuropathol Appl Neurobiol. 2013 Jun;39(4):417-25. doi: 10.1111/j.1365-2990.2012.01288.x.

PMID:
22758774

Supplemental Content

Support Center